BlueRock Therapeutics phase I clinical trial for Parkinson’s disease continues to show positive trends at 18 months.

*Investigational cell therapy bemdaneprocel continues to be well tolerated with no major safety issues in all 12 participants in low and high dose cohorts through 18 months

*After stopping the 12-month immune suppression regimen,assessment of 18-month data shows evidence of sustained cell engraftment and increased F-DOPA signal

*Exploratory clinical endpoints continued to improve from 12 to 18 months,with participants in the high dose cohort showing greater improvement compared to the low dose cohort

*A phase II study is expected to begin enrolling participants later this year

（来源/www.bluerocktx.com）